Ipsen is committed to long-term follow-up with the patient registry program, which monitors long-term safety and efficacy of Increlex.
Increlex is the only FDA-approved medicine for the long-term treatment of growth failure in children with severe Primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.1
In the years of clinical research and trials conducted to gain FDA approval of Increlex, no subject withdrew from any study due to adverse events.1 However, it is important to consider certain adverse reactions and treatment precautions. Treatment with Increlex should be directed by physicians who are experienced in the diagnosis and management of patients with growth disorders.
For a complete list of adverse reactions and treatment precautions click here
Increlex should not be used for growth promotion in patients with1:
Hypoglycemia was the most common adverse event reported for 30 subjects (42%); 14 (47%) of whom had prior history.1 Five subjects had severe hypoglycemia requiring assistance and treatment on one or more occasion and 4 of these subjects had seizures.1 The frequency of hypoglycemia was highest in the first month of treatment. Hypoglycemic episodes were more frequent in younger children but were generally avoided when a meal or snack was consumed shortly before or after administration of Increlex.1
Getting to know your patients and understanding their history can help you determine whether or not pre-prandial glucose monitoring is necessary. If hypoglycemia occurs with recommended doses, despite adequate food intake, the dose should be reduced.1
Tonsillar hypertrophy was noted in 11 (15%) subjects in the first 1 to 2 years of therapy with lesser tonsillar growth in subsequent years.1
Examine your patient's tonsils, pharynx, and adenoids. Be sure to inquire about snoring, difficulty swallowing and sleep apnea during treatment as these issues may be due to tonsillar hypertrophy.
Intracranial hypertension occurred in three subjects.1 For two of the three subjects, the events resolved without interruption of Increlex treatment.1 One subject discontinued and resumed later at a lower dose without recurrence.1 Funduscopic examination is recommended at the initiation and periodically during the course of Increlex therapy to rule out presence of papilledema.1
Lipohypertrophy was noted in 24 subjects (32%)7 and was associated with lack of proper rotation of injection sites.7,30 This resolved when injections were properly rotated.7 It was most pronounced in 3 subjects who had the poorest overall growth response.30
Increlex injection sites should be rotated to a different site with each injection.1 Educating your patients and caregivers about the importance of rotating the injection sites ultimately will benefit everyone.
Ipsen is committed to the ongoing collection of long-term data and has established the Increlex Growth Forum Database (IGFD); a patient registry program monitoring the long-term safety and efficacy of Increlex. It allows physicians to register and enter information regarding their experiences with Increlex on a real-time basis. Over 650 patients are enrolled and this number will continue to grow.29 For more information or to contact a Clinical Registry Liaison, click here.
INCRELEX® (mecasermin [rDNA origin] injection) is indicated for the treatment of growth failure in children with severe primary IGF-1 deficiency, or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. Severe primary IGF-1 deficiency (IGFD) is defined by height standard deviation score ≤ -3.0 and basal IGF-1 standard deviation score ≤ -3.0 and normal or elevated growth hormone (GH). Severe Primary IGFD includes classical and other forms of growth hormone insensitivity. Patients with Primary IGFD may have mutations in the GH receptor (GHR), post-GHR signaling pathway including the IGF-1 gene. They are not GH deficient, and therefore, they cannot be expected to respond adequately to exogenous GH treatment.
INCRELEX is not intended for use in subjects with secondary forms of IGF-1 deficiency, such as GH deficiency, malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids. Thyroid and nutritional deficiencies should be corrected before initiating INCRELEX treatment.
Limitations of use: INCRELEX is not a substitute to GH for approved GH indications.
INCRELEX is contraindicated in the presence of active or suspected malignancy, and therapy should be discontinued if evidence of malignancy develops. INCRELEX should not be used by patients who are allergic to mecasermin (rhIGF-1) or any of the inactive ingredients in INCRELEX, or who have experienced a severe hypersensitivity to INCRELEX [see Warnings and Precautions and Adverse Reactions]. Intravenous administration of INCRELEX is contraindicated. INCRELEX should not be used for growth promotion in patients with closed epiphyses.
INCRELEX has insulin-like hypoglycemic effects and should be administered 20 minutes before or after a meal or snack. Hypersensitivity and allergic reactions have been reported, including a low number of cases indicative of anaphylaxis requiring hospitalization. Intracranial hypertension has occurred in patients treated with INCRELEX. Funduscopic examination is recommended at the initiation of and periodically during the course of therapy. Patients should have periodic examinations to rule out potential complications from tonsillar/adenoidal hypertrophy and receive appropriate treatment if necessary. Children with onset of limp or hip/knee pain should be evaluated for possible slipped capital femoral epiphysis. Monitor any child with scoliosis for progression of the spine curve.
In clinical studies of 71 pediatric subjects with severe Primary IGFD representing 274 patient-years of treatment, no subjects discontinued due to adverse events. Hypoglycemia was reported by 30 subjects (42%) at least once during their course of therapy with INCRELEX. Most cases of hypoglycemia were mild or moderate in severity. Five subjects had severe hypoglycemia (requiring assistance and treatment) on one or more occasion and four subjects experienced hypoglycemic seizures/loss of consciousness on one or more occasion. Symptomatic hypoglycemia was generally avoided when a meal or snack was consumed either shortly (i.e., 20 minutes) before or after the administration of INCRELEX. Tonsillar hypertrophy was noted in 11 (15%) subjects in the first 1 to 2 years of therapy with lesser tonsillar growth in subsequent years. Intracranial hypertension occurred in three subjects. In two subjects the events resolved without interruption of INCRELEX treatment. INCRELEX treatment was discontinued in the third subject and resumed later at a lower dose without recurrence.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit , or call 1-800-FDA-1088.